The monoclonal antibody trastuzumab (Herceptin®), which targets the human epidermal
growth factor receptor 2 (HER2), is approved for the treatment of early breast and advanced …

Trastuzumab improves survival outcomes for patients with HER2-positive (HER2+) breast
cancer, yet not all such women receive this important therapy. Trastuzumab was approved …

ABSTRACT A biosimilar product needs to demonstrate biosimilarity to the originator
reference product, and the quality profile of the latter should be monitored throughout the …

Purpose This phase III study compared SB3, a trastuzumab (TRZ) biosimilar, with reference
TRZ in patients with human epidermal growth factor receptor 2–positive early breast cancer …

Background The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and
the trastuzumab reference product (TRZ) in terms of the breast pathologic complete …

Biosimilars are considered to be one of the solutions to combat the substantially increasing
costs of cancer treatment, and its imminent introduction is expected to expand affordability …

Biosimilars have the potential to broaden patient access to biologics and provide cost
savings for health care systems. During the development of a biosimilar, data that directly …

The utilization of trastuzumab biosimilar medications is of particular interest in HER2-
positive breast cancer as these drugs have the potential for cost savings and increased …

Purpose This study evaluated the bioequivalence of China-manufactured biosimilar, HLX02,
to reference China (CN)-and European Union (EU)-sourced trastuzumab. Methods This was …

SB3 is a biosimilar of trastuzumab that has been approved for use in the treatment of human
epidermal growth factor 2-positive breast cancer and human epidermal growth factor 2 …